跳至主要内容
临床试验/NCT00763685
NCT00763685终止4 期

Double-Blind, Randomized, Placebo -Controlled Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

East Tallinn Central Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
40
试验地点
1
主要终点
Pain scale

研究概览

简要总结

Primary Hypothesis:

  1. The analgesic effect of etoricoxib 120 mg administered 1 hour preoperatively is greater than that of placebo in the treatment of postoperative pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Type of gynaecologic surgery:
  • diagnostic laparoscopy
  • sterilization
  • removal of ovarial cyst
  • chromopertubation
  • laparoscopic myomectomy
  • laparoscopic fenestration of ovaria
  • laparoscopic adhesiolysis
  • Age 18-50 years.
  • Evaluated risk of anaesthetic procedure according to ASA (American Society of Anaesthesiologist) classification: ASA I or II.
  • Patients agreed to participate in the study and signed the informed consent.

排除标准

  • ASA III or more
  • Emergency surgery
  • Major laparoscopic surgery i.e. hysterectomy
  • Duration of surgery more than 90 minutes
  • Chronic pain
  • History of hypersensitivity to the active substance or to any of the excipients of study drug (Paracetamol or Etoricoxib)
  • Active peptic ulceration or active gastro-intestinal (GI) bleeding.
  • Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
  • Pregnancy and lactation
  • Severe hepatic dysfunction (serum albumin < 25 g/l or Child-Pugh score ≥ 10).
  • Estimated renal creatinine clearance < 30 mL/min.
  • Children and adolescents under 16 years of age.
  • Inflammatory bowel disease.
  • Congestive heart failure (NYHA II-IV).
  • Patients with hypertension whose blood pressure has not been adequately controlled.
  • Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease, unstable angina.
  • Patient has undergone coronary artery bypass graft surgery, angioplasty, or had myocardial infarction, cerebrovascular accident or transient ischemic attack within the past 6 months.
  • History of drug abuse.

研究组 & 干预措施

etoricoxib 120 mg

Active Comparator

active control

干预措施: etoricoxib (Drug)

2

Placebo Comparator

Placebo

干预措施: etoricoxib (Drug)

3

Active Comparator

Paracetamol 1 g and etoricoxib 120 mg

干预措施: etoricoxib (Drug)

结局指标

主要结局

Pain scale

时间窗: 24 hours

次要结局

  • Vomiting(24 hours)

研究者

发起方
East Tallinn Central Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tiina Arumagi

anaesthesiologist

East Tallinn Central Hospital

研究点 (1)

Loading locations...

相似试验